|
National Institutes of Health |
 |
 |
|
"We share your belief that the overall approach may be a sound one, which has not been well-studied to date, and hope that our present trials will provide some initial scientific insights into the potential salutary effects of immune down-regulation that will spur us to continue our investigations in this area. Should that turn out to be the case, we agree that the cannabinoids may be an appropriate class of compounds for further study in this regard."
Richard Davey, M.D., Deputy Clinical Director of the Office of Clinical Research, NIAID, The NIH, June 27, 2005 (Personal Communication)
|
